Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice

X. Leleu, HC. Lee, JA. Zonder, M. Macro, K. Ramasamy, C. Hulin, J. Silar, M. Kuhn, K. Ren, N. Bent-Ennakhil, D. Cherepanov, DM. Stull, E. Terpos

. 2024 ; 20 (14) : 935-950. [pub] 20240110

Language English Country England, Great Britain

Document type Meta-Analysis, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24006501

Grant support
Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA

Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006501
003      
CZ-PrNML
005      
20240423155323.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2023-0604 $2 doi
035    __
$a (PubMed)38197267
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Leleu, Xavier $u Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, 86000, France $1 https://orcid.org/0000000298224170
245    10
$a INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice / $c X. Leleu, HC. Lee, JA. Zonder, M. Macro, K. Ramasamy, C. Hulin, J. Silar, M. Kuhn, K. Ren, N. Bent-Ennakhil, D. Cherepanov, DM. Stull, E. Terpos
520    9_
$a Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.
650    _2
$a lidé $7 D006801
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a sloučeniny boru $x terapeutické užití $7 D001896
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    12
$a glycin $x analogy a deriváty $7 D005998
650    _2
$a lenalidomid $x terapeutické užití $7 D000077269
650    _2
$a multicentrické studie jako téma $7 D015337
650    12
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a prospektivní studie $7 D011446
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a metaanalýza $7 D017418
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lee, Hans C $u M.D. Anderson Cancer Center, Houston, TX 77030, USA
700    1_
$a Zonder, Jeffrey A $u Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI 48201, USA
700    1_
$a Macro, Margaret $u CHU de Caen, Caen, 14000, France
700    1_
$a Ramasamy, Karthik $u Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, OX3 7LE, UK
700    1_
$a Hulin, Cyrille $u CHU de Bordeaux, Bordeaux, 33000, France
700    1_
$a Silar, Jiri $u Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic
700    1_
$a Kuhn, Matyas $u Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic
700    1_
$a Ren, Kaili $u Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA
700    1_
$a Bent-Ennakhil, Nawal $u Takeda Pharmaceuticals International AG, Opfikon, 8152, Switzerland
700    1_
$a Cherepanov, Dasha $u Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA
700    1_
$a Stull, Dawn Marie $u Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA
700    1_
$a Terpos, Evangelos $u Department of Clinical Therapeutics, National & Kapodistrian University of Athens, School of Medicine, Athens,115 27, Greece
773    0_
$w MED00008687 $t Future oncology $x 1744-8301 $g Roč. 20, č. 14 (2024), s. 935-950
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38197267 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155320 $b ABA008
999    __
$a ok $b bmc $g 2080849 $s 1216268
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 20 $c 14 $d 935-950 $e 20240110 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
GRA    __
$p Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options